KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBT: 2009-2024

Historic EBT for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $4.8 billion.

  • Regeneron Pharmaceuticals' EBT rose 18.10% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 billion, marking a year-over-year increase of 3.54%. This contributed to the annual value of $4.8 billion for FY2024, which is 13.83% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported EBT of $4.8 billion as of FY2024, which was up 13.83% from $4.2 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' EBT's 5-year high stood at $9.3 billion during FY2021, with a 5-year trough of $3.8 billion in FY2020.
  • Its 3-year average for EBT is $4.6 billion, with a median of $4.8 billion in 2024.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EBT spiked by 144.75% in 2021, and later plummeted by 47.90% in 2022.
  • Yearly analysis of 5 years shows Regeneron Pharmaceuticals' EBT stood at $3.8 billion in 2020, then soared by 144.75% to $9.3 billion in 2021, then plummeted by 47.90% to $4.9 billion in 2022, then fell by 13.57% to $4.2 billion in 2023, then rose by 13.83% to $4.8 billion in 2024.